93006-71-4

Upstream product

• 105-53-3 diethyl malonate 
• 1794-48-5 1-bromo-3-phenylprop-2-yne 
• 17920-23-9 diethyl propargylmalonate 
• 591-50-4 iodobenzene 
• 1504-58-1 3-Phenyl-2-propyn-1-ol 
• 536-74-3 phenylacetylene 
• 23431-56-3 (4-bromobut-1-yn-1-yl)benzene 
• 996-82-7 sodium diethylmalonate 

Downstream Products

• 91368-76-2 (3-phenyl-prop-2-ynyl)-malonic acid 
• 131529-87-8 ethyl 5-phenyl-4-pentynoate 
• 1037294-62-4 diethyl 1-phenyl-6-octen-1-yne-4,4-dicarboxylate 
• 143668-01-3 5-oxo-6-phenyl-3,3a,4,5-tetrahydro-1H-pentalene-2,2-dicarboxylic acid diethyl ester 
• 143633-91-4 diethyl 2-allyl-2-(3-phenylprop-2-yn-1-yl)malonate 
• 4055-00-9 6-phenyl-3,4-dihydropyran-2-one 
• 49828-17-3 1,6-diphenyl-3,4-dihydro-1H-pyridin-2-one 
• 167173-20-8 diethyl 2-(3-phenylprop-2-yn-1-yl)-2-(prop-2-yn-1-yl)malonate 
• 1259284-01-9 C₂₄H₂₅NO₅ 

Relevant academic research and scientific papers

Iron-Catalyzed [2+2+2] Annulation of Aliphatic Bridged 1,n-Enynes with Aldehydes for the Synthesis of Fused Pyrans

An iron-catalyzed [2+2+2] annulation of aliphatic bridged 1,n-enynes with aldehydes was developed. Aldehydes play a dual role as the precursors of acyl radicals to trigger the cascade cyclization but also as the radical acceptors to terminate the annulation. This two-in-one strategy overcomes the limitation in [2+2+m] cyclization that requires a rigid benzene skeleton as the essential linker, thus enabling the efficient synthesis of functionalized fused [5.6] and [6.6] pyran skeletons.

Cyclization of alk-5-ynyl ketones promoted by Tf2NH and In(OTf)3: selective synthesis of 5- and 7-membered carbocycles

Combined use of Tf2NH and In(OTf)3effectively promotes the cyclization of alk-5-ynyl ketones to cyclopent-1-enyl ketones at 30?°C. Single use of Tf2NH or In(OTf)3requires heating at 50?°C for efficient cyclizati

LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS

Disclosed herein are compounds of formula (I) wherein L1, L2, L3, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.

METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH

The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.

LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS

Disclosed herein are compounds of formula (I) wherein L 1 , L 2 , L 3 , L 4 , R 1 , R 4 , R 5 , R 6 , and s are as defined in the specification. Compounds of formula (I) are EP 4 agonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.

CoCl(PPh3)3 as Cyclotrimerization Catalyst for Functionalized Triynes under Mild Conditions

The ubiquitary Co(I) complex CoCl(PPh3)3 was found to be a convenient catalyst for the [2 + 2 + 2] cycloaddition of functionalized triynes under mild reaction conditions and devoid of any additional additive, yielding the substituted

DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS

Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification.

LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS

Disclosed herein are compounds of formula (I) wherein L1, L2, L3, R1, R4, R5, and R6 are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.

Scope of the intramolecular titanocene-catalyzed Pauson-Khand type reaction

A Pauson-Khand type conversion of enynes to bicyclic cyclopentenones employing the commercially available precatalyst titanocene dicarbonyl is described. This methodology shows excellent functional group tolerance for a group 4 metallocene-catalyzed process. The scope and limitations of this cyclization with respect to 1,6-, 1,7- and 1,8-enynes with a variety of terminal alkyne substituents, chiral enynes, and enynes containing substituted olefins are described in detail. A mechanism involving carbonylation of an intermediate titanacyclopentene has been proposed.

New anionic cyclization of 4- and 5-alkynylamines: Synthesis of 2-Benzylidene pyrrolidines and piperidines

Treatment of 4- and 5-alkynylamines with 0.5-1.2 equiv. of butyllithium brought about a facile anionic cyclization, giving the corresponding enamine pyrrolidines and piperidines having an exo double bond in high yields. Treatment of 4-alkynamides with lit